162 related articles for article (PubMed ID: 15034674)
1. CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response.
Sfondrini L; Besusso D; Bronte V; Macino B; Rossini A; Colombo MP; Ménard S; Balsari A
Cancer Immunol Immunother; 2004 Aug; 53(8):697-704. PubMed ID: 15034674
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
[TBL] [Abstract][Full Text] [Related]
3. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
4. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.
Kawarada Y; Ganss R; Garbi N; Sacher T; Arnold B; Hämmerling GJ
J Immunol; 2001 Nov; 167(9):5247-53. PubMed ID: 11673539
[TBL] [Abstract][Full Text] [Related]
5. Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses.
Kochenderfer JN; Chien CD; Simpson JL; Gress RE
J Immunol; 2006 Dec; 177(12):8860-73. PubMed ID: 17142789
[TBL] [Abstract][Full Text] [Related]
6. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
[TBL] [Abstract][Full Text] [Related]
8. Absence of the CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice.
Sfondrini L; Besusso D; Zoia MT; Rodolfo M; Invernizzi AM; Taniguchi M; Nakayama T; Colombo MP; Ménard S; Balsari A
J Immunol; 2002 Jul; 169(1):151-8. PubMed ID: 12077240
[TBL] [Abstract][Full Text] [Related]
9. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.
Alizadeh D; Zhang L; Brown CE; Farrukh O; Jensen MC; Badie B
Clin Cancer Res; 2010 Jul; 16(13):3399-408. PubMed ID: 20570924
[TBL] [Abstract][Full Text] [Related]
10. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.
Buhtoiarov IN; Sondel PM; Eickhoff JC; Rakhmilevich AL
Immunology; 2007 Mar; 120(3):412-23. PubMed ID: 17163960
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection.
Rhee EG; Mendez S; Shah JA; Wu CY; Kirman JR; Turon TN; Davey DF; Davis H; Klinman DM; Coler RN; Sacks DL; Seder RA
J Exp Med; 2002 Jun; 195(12):1565-73. PubMed ID: 12070284
[TBL] [Abstract][Full Text] [Related]
12. Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity.
Cerkovnik P; Novakovic BJ; Stegel V; Novakovic S
BMC Immunol; 2010 Sep; 11():45. PubMed ID: 20836870
[TBL] [Abstract][Full Text] [Related]
13. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
15. Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.
Ginzkey C; Eicker SO; Marget M; Krause J; Brecht S; Westphal M; Hugo HH; Mehdorn HM; Steinmann J; Hamel W
Cancer Immunol Immunother; 2010 Apr; 59(4):541-51. PubMed ID: 19798500
[TBL] [Abstract][Full Text] [Related]
16. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice.
Liu Y; Luo X; Yang C; Yu S; Xu H
Vaccine; 2011 Aug; 29(34):5778-84. PubMed ID: 21664398
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice.
Gramzinski RA; Doolan DL; Sedegah M; Davis HL; Krieg AM; Hoffman SL
Infect Immun; 2001 Mar; 69(3):1643-9. PubMed ID: 11179339
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response.
Pan J; Zhang M; Wang J; Wang Q; Xia D; Sun W; Zhang L; Yu H; Cao X
J Cancer Res Clin Oncol; 2005 Jul; 131(7):468-78. PubMed ID: 15711825
[TBL] [Abstract][Full Text] [Related]
19. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro.
Rothenfusser S; Hornung V; Ayyoub M; Britsch S; Towarowski A; Krug A; Sarris A; Lubenow N; Speiser D; Endres S; Hartmann G
Blood; 2004 Mar; 103(6):2162-9. PubMed ID: 14630815
[TBL] [Abstract][Full Text] [Related]
20. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.
Speiser DE; Liénard D; Rufer N; Rubio-Godoy V; Rimoldi D; Lejeune F; Krieg AM; Cerottini JC; Romero P
J Clin Invest; 2005 Mar; 115(3):739-46. PubMed ID: 15696196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
